We selectively partner our programs in order to accelerate timelines and better align resources.
Theravance Biopharma and Janssen Biotech, Inc. entered into a strategic collaboration to develop TD-1473 (an intestinally restricted JAK inhibitor) and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease.
Theravance Biopharma has developed YUPELRI® (revefenacin) inhalation solution, under a strategic collaboration with Mylan. Mylan and Theravance co-commercialize the product in the United States.
Takeda Pharmaceutical Company Limited has a global license, development and commercialization agreement for TD-8954, a selective 5-HT4 receptor agonist, for potential use in the treatment of a variety of gastrointestinal motility disorders.
Alfasigma (S.p.A.) is developing Velusetrag for the treatment of gastrointestinal motility disorders under a license from Theravance Biopharma. Velusetrag is a highly selective investigational 5-HT4 receptor agonist.
Cumberland Pharmaceuticals holds global rights to VIBATIV® (telavancin), a proprietary antibiotic discovered and developed by Theravance Biopharma.
Theravance Biopharma and Pfizer Inc. have entered into a global license agreement for Theravance Biopharma's preclinical program for skin-selective, locally-acting pan-Janus kinase (JAK) inhibitors. The compounds in this program are designed to target validated pro-inflammatory pathways and are specifically designed to possess skin-selective activity with minimal systemic exposure.